Nasdaq cprx.
Catalyst Pharmaceuticals (NASDAQ:CPRX) is another biotech that has performed strongly over the past twelve months. During this timeframe, shares have nearly doubled in price. During this timeframe ...
Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have lost about 16.2% in that time frame, underperforming the S&P 500.Their CPRX share price targets range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next twelve months. This …Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you...
January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...
Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Aug 9, 2023 · CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update.
For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...Shareholders of Catalyst Pharmaceuticals ( CPRX -1.13%) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries ( TEVA -1.12%), was planning to ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. Tesla, Inc ...Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you... Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...
Discover historical prices for PCRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Pacira BioSciences, Inc. stock was issued.
Feb 27, 2023 · For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...
For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with..CPRX earnings call for the period ending September 30, 2021. Image source: The Motley Fool. Catalyst Pharmaceuticals, inc ( CPRX -1.16% ) Q3 2021 Earnings Call Nov 10, 2021 , 8:30 a.m. ETOct 16, 2023 · Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine). Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. …
Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second …Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 70% over the last three months. Given the company's impressive performance, we ...Oct 16, 2023 · Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine). View Information. Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. Uncover the latest insider trading activity for Catalyst Pharmaceuticals, Inc. (CPRX). Know which insiders are buying and selling along with top shareholders and ownership breakdown.CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
Firdapse is also being studied in a proof-of-concept spinal muscular atrophy type-3 study, with top-line data expected before year-end. CPRX closed Monday's trading at $4.26, up 5.31%.The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 12.30x, while the 36-month beta value is 1.08.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.) Jul-19- ...Fintel reports that on August 22, 2023, Cantor Fitzgerald reiterated coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 56.49% UpsideFintel reports that on August 22, 2023, Cantor Fitzgerald reiterated coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 56.49% UpsideStock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Cetera Investment Advisers grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the second …Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, engaged in the development and commercialization of therapies for rare debilitating ...
The stock of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has increased by 5.94 when compared to last closing price of 12.63.Despite this, the company has seen a gain of 4.12% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results.
Analyst Andrew Fein of H.C. Wainwright has scored a 100% success rate on his views on Catalyst Pharmaceuticals (NASDAQ:CPRX) stock.Fein is an expert in tracking U.S.-based Healthcare companies ...
10 jam yang lalu ... Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) appoints Michael W. Kalb as Executive Vice President and Chief Financial Officer, ...Mar 31, 2020 · Find the latest Revenue & EPS data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Catalyst Pharmaceuticals Q3 Adjusted Profit, Revenue Rise; Lifts 2023 Guidance. Nov. 09. MT. Earnings Flash (CPRX) CATALYST PHARMACEUTICALS …Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...14 jam yang lalu ... Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and ...Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ETCompany Participants. Patrick McEnany - Chairman, Chief Executive Officer. Alicia Grande - Vice ...Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) · Latest CPRX News | Press Releases · Today's Trading · Growth & Valuation · Competitors · Financials · Profile · Forecasts.Fintel reports that on August 22, 2023, Cantor Fitzgerald reiterated coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 56.49% UpsideCatalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.
Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known ...(CPRX). NASDAQ: CPRX · IEX Real-Time Price · USD. Add to Watchlist. 14.06. +0.20 (1.44%). At close: Nov 24, 2023, 1:00 PM. 13.82. -0.24 (-1.71%). After-hours: ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company. To get a sense of who is truly in …Instagram:https://instagram. how to get into forex1943 metal penny worthbest medicare advantage plans in florida 2023risky but high return investments TipRanks | Stock Market Research, News and Analyst Forecasts ... Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with.. daymark wealth partnersstock toyota Jan 31, 2023 · Catalyst Pharma (NASDAQ:CPRX) is a $1.6bn market cap (at the time of writing) Florida based commercial stage biotech that markets and sells a single product - the neuronal potassium channel ... gls 600 The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.Aug 2, 2023 · Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% Upside